Waaxda Caalamiga ah

Janaayo 22, 2025, "Daawada Dabeecadda" waxay daabacday natiijooyinka Akeso si madax-bannaan u samaysay cadonilimab antibody bispecific ah oo PD-1/CTLA-4 ah oo lagu daray oxaliplatin iyo capecitabine si loogu daaweeyo safka koowaad ee cudurka caloosha ama caloosha ee aan la tirtiri karin ee maxalliga ah ama aan la daaweyn karin...Akhriso wax dheeraad ah»

Janaayo 8, 2025, Maamulka Badeecadaha Caafimaadka Qaranka ee Shiinaha (NMPA) ayaa ansixiyay PADCEVTM (enfortumab vedotin) oo ay weheliso KEYTRUDA (pembrolizumab) bukaanada qaangaarka ah ee qaba kansarka kaadi-mareenka ee maxalliga ah ama kansarka kaadi-mareenka ee faafa (la/mUC). Ansixinta NMPA ee enfortumab vedotin ee shanlada...Akhriso wax dheeraad ah»

Febraayo 17, 2025, Innovent Biologics waxay ku dhawaaqday in borotiinkeeda isku-darka antibody-ga ee heerka koowaad ee PD-1/IL-2α-bias, IBI363, uu helay Magacaabista Degdegga ah ee labaad (FTD) oo ka timid Maamulka Cuntada iyo Dawooyinka ee Mareykanka (FDA). Magacaabistani waxay khuseysaa daaweynta aan la tirtiri karin, ...Akhriso wax dheeraad ah»

Janaayo 16, 2025, IMPACT waxay ku dhawaaqday in Kaabsulka Senaparib (派舒宁®) uu ka helay ogolaansho suuqgeyn ah Shiinaha Maamulka Badeecadaha Caafimaadka Qaranka (NMPA) oo ah daaweyn hal-daaweyn ah oo loogu talagalay daaweynta dayactirka bukaanada qaangaarka ah ee qaba epithelial-ka sare (FIGO Marxaladaha III iyo IV) oo heer sare ah...Akhriso wax dheeraad ah»

Febraayo 7, 2025, Sichuan Kelun-Biotech Biopharmaceutical waxay ku dhawaaqday ansixinta duritaanka Cetuximab N01 ee Maamulka Qaranka ee Waxsoosaarka Caafimaadka si loogu daaweeyo kansarka mindhicirka ee metastatic (mCRC) ee Shiinaha. Ansixinta waxay ku salaysan tahay daraasad caafimaad oo heer sare ah oo wejiga saddexaad ah...Akhriso wax dheeraad ah»

Febraayo 10, 2025, CARsgen Therapeutics waxay ku dhawaaqday in qofka ugu horreeya ee lagu daaweeyay daaweyn allogeneic BCMA CAR-T ah oo lagu sameeyay madal THANK-u Plus™, uu gaaray jawaab celin dhammaystiran oo adag (sCR) iyo taban yar oo cudurka haray (MRD) ah qiimaynta Maalinta-28. Waxaa lagu sameeyay gudaha...Akhriso wax dheeraad ah»

Janaayo 29, 2025, koox cilmi-baaris Shiineys ah ayaa daabacday maqaal cinwaankiisu yahay "Neoadjuvant pyrotinib iyo trastuzumab ee kansarka naasaha ee HER2 oo aan lahayn jawaab celin hore (NeoPaTHer): waxtarka, badbaadada, iyo falanqaynta biomarker ee daraasad la filayo, xarun badan, oo la waafajiyay jawaab celin" ee th...Akhriso wax dheeraad ah»

Janaayo 26, 2025, Xarunta Qiimaynta Daawada (CDE) ee Maamulka Badeecadaha Caafimaadka Qaranka ee Shiinaha ayaa ku dhawaaqday in duritaanka LM-108 loogu talagalay in lagu daro daaweynta degdegga ah ee burooyinka adag ee horumarsan ee leh xasillooni darro microsatellite ah (MSI-H) ama cilladaha dayactirka aan isku midka ahayn (dMMR)...Akhriso wax dheeraad ah»

Janaayo 20, Maamulka Badeecadaha Caafimaadka Qaranka (NMPA) wuxuu ansixiyay daaweynta isku-dhafka ah ee monoclonal antibody tagitanlimab (oo hore loogu yaqaanay KL-A167) ee cisplatin iyo gemcitabine si loogu daaweeyo bukaanka kansarka nasopharyngeal ee soo noqnoqda ama metastatic (NPC). ...Akhriso wax dheeraad ah»

Janaayo 16, 2025, Maamulka Badeecadaha Caafimaadka Qaranka ee Shiinaha (NMPA) ayaa ansixiyay Codsiga Daawada Cusub (NDA) ee limertinib si loogu daaweeyo bukaanada qaangaarka ah ee qaba kansarka sambabka unugyada yaryar ee aan la beddelin ee EGFR T790M (NSCLC) ee maxalliga ah ama horumarsan. Ku saabsan Limertinib Limertinib ...Akhriso wax dheeraad ah»

Janaayo 8, Xarunta Qiimaynta Daawada (CDE) ee Maamulka Badeecadaha Caafimaadka Qaranka ee Shiinaha (NMPA) ayaa u aqoonsatay Magacaabista Daaweynta Degdegga ah (BTD) IBI343, oo ah TOPO1i anti-CLDN18.2 ADC oo heer sare ah, inay tahay daaweyn hal-hal ah oo loogu talagalay daaweynta pancr-ka horumarsan ee CLDN18.2-positive...Akhriso wax dheeraad ah»

Janaayo 8, 2025, 9MW2821 waxaa la siiyay Magacaabista Daaweynta Degdegga ah (BTD) Xarunta Qiimaynta Daawada (CDE) ee Maamulka Badeecadaha Caafimaadka Qaranka (NMPA) ee Shiinaha.9MW2821 waxaa la siiyaa iyadoo lagu darayo toripalimab, oo ah antibody monoclonal ah oo ka hortagga PD-1, si loogu daaweeyo - aan la garanayn, aan la daaweyn karin...Akhriso wax dheeraad ah»